非传统的T细胞影响异构血型细胞移植后临床结果
Lama Siblany1,2, Nicolas Stocker1,2, Laure Ricard1,2
1INSERM, Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, F-75012, Paris, France.
Journal of clinical immunology
|June 1, 2024
概括
在全基造血细胞移植 (allo-HCT) 后,粘膜相关的不变T细胞 (MAIT) 和特定的玛-三角形 (γδ) T细胞子集的早期恢复显著改善了患者的生存率,并减少了GvHD. MAIT细胞频率和Vδ2+T细胞上的CD26表达是成功的alo-HCT结果的关键指标.
科学领域:
- 免疫学 免疫学 免疫学
- 移植科学 移植科学
- 细胞疗法细胞疗法
背景情况:
- 全基性造血细胞移植 (allo-HCT) 的结果受到免疫细胞重构的影响.
- 粘膜相关的不变T细胞 (MAIT) 和玛-三角形 (γδ) T细胞,特别是Vδ2+ T细胞,在移植后的免疫反应中起作用.
- 了解这些T细胞子集对临床结果的具体贡献对于优化allo-HCT至关重要.
研究的目的:
- 评估MAIT细胞和Vδ2+T细胞子集早期恢复对接受alo-HCT的76名患者临床结果的影响.
- 分析移植后MAIT和Vδ2+T细胞的功能特征 (细胞毒性,细胞因子产生).
- 为了将T细胞频率和激活标记与无移植对宿主疾病 (GvHD),无复发生存率 (GRFS),总生存率 (OS) 和无疾病生存率 (DFS) 相关联.
主要方法:
- 流细胞测量被用来识别和量化MAIT细胞 (CD3+ TCRVα7.2+CD161+) 和Vδ2+ T细胞子集 (通过CD26表达区分) 在Allo-HCT后20-30天.
- 在体外激活后,评估了穿孔素,B粒酶 (细胞毒性标志物) 和IFN-γ的细胞内水平.
- 临床结局,包括GRFS,OS,DFS,急性GvHD (aGvHD) 和非复发性死亡率,与T细胞恢复相关分析.
主要成果:
- 在HCT后20-30天的MAIT细胞频率更高与GRFS,OS和DFS的增加显著相关.
- 在MAIT细胞上CD69表达低的患者中, 2-4级aGvHD的发病率更高.
- 高频率的CD26+ Vδ2+ T细胞与显著更高的GRFS,OS和DFS相关,但没有影响aGvHD或死亡率.
结论:
- 早期的MAIT细胞复制,受激活标记物的影响,可能会在alo-HCT后的早期缓解不良影响.
- CD26+ Vδ2+ T 细胞的频率是继 allo-HCT 治疗后改善生存结果的重要预测指标.
- 这些发现突显了MAIT和特定Vδ2+T细胞子集作为预测Allo-HCT成功的生物标志物的潜力.
相关概念视频
Cell-mediated Immune Responses
68.1K
Overview
68.1K
T Cell Activation and Clonal Selection
706
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
706
Bone Marrow Sampling and Transplants
324
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
324
Tumor Immunotherapy
514
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
514
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K


